Non-viral platform technology
Mediphage is a leading biotechnology research company dedicated to developing innovative non-viral gene therapies. With a focus on creating safe and redosable treatments, Mediphage employs its flagship technology, ministring DNA (msDNA), a versatile linear covalently closed (LCC) DNA construct capable of accommodating large transgenes. This groundbreaking approach addresses various applications, paving the way for significant advancements in therapeutic solutions.
Located at 661 University Avenue, 1300, Toronto, Ontario M5G 0B7, CA, Mediphage is committed to evaluating the therapeutic potential of its non-viral platform technology across a number of indications, both internally and through external collaborations. By leveraging cutting-edge research and strategic partnerships, Mediphage is poised to make a substantial impact on the future of biotechnology.
Mediphage continues to push the boundaries of biotechnology research, and we invite the Mediphage management team to create a customized and exclusive company showcase and product listing on our platform, further highlighting their contributions to the field.
Mediphage est une entreprise de recherche biotechnologique de premier plan dédiée au développement de thérapies géniques non virales innovantes. En mettant l'accent sur la création de traitements sûrs et redosables, Mediphage utilise sa technologie phare, l'ADN ministring (msDNA), une construction d'ADN linéaire covalentement fermée (LCC) polyvalente capable d'accueillir de grands transgènes. Cette approche révolutionnaire aborde diverses applications, ouvrant la voie à des avancées significatives dans les solutions thérapeutiques.
Située au 661 University Avenue, 1300, Toronto, Ontario M5G 0B7, CA, Mediphage s'engage à évaluer le potentiel thérapeutique de sa technologie de plateforme non virale dans un certain nombre d'indications, à la fois en interne et par le biais de collaborations externes. En tirant parti de la recherche de pointe et des partenariats stratégiques, Mediphage est sur le point d'avoir un impact substantiel sur l'avenir de la biotechnologie.
Mediphage continue de repousser les limites de la recherche biotechnologique, et nous invitons l'équipe de direction de Mediphage à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme, soulignant davantage leurs contributions au domaine.
Compare Mediphage with 3 companies in Biotechnology-Research
| Comparison Field |
MediphageMain Company |
Graphite BioView Profile |
Encoded Therapeutics...View Profile |
Pacira GermanyView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2020 | 2014 | 2012 |
|
Company Size
|
— | 51-200 | 51-200 | 11-50 |
|
City
|
Toronto, Ontario | South San Francisco, CA | South San Francisco, California | |
|
Country
|
Canada | United States | United States | |
|
Skills & Keywords
Comparing with main company
|
16 Total Skills
Gene Therapy
Biotechnology
DNA
Non-Viral Vectors
Genetic Engineering
Pharmaceuticals
Research and Development
plasmids for AAV manufacturing
CNS
DNA Vaccine
non-viral vectors
gene editing
gene therapy
Retina
biotechnology
Hemophilia
|
4 Total
4 Unique
Unique Skills:
clinical development
CRISPR
research
sickle cell disease
|
2 Total
2 Unique
Unique Skills:
healthcare
therapeutics
|
5 Total
5 Unique
Unique Skills:
animal health
drug development
human medicine
musculoskeletal disease
osteoarthritis
|
Other organizations in the same industry
This company is also known as